Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25042203 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Montserrat Fernández-Guarino und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hospital Universitario Ramón y Cajal, Instituto de Investigación Sanitaria Ramón y Cajal (Irycis), 28034 Madrid, Spain. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome, Leukemia-Lymphoma, Adult T-Cell. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kyowa Kirin.
Abstract (Originalsprache)
Mogamulizumab (MOG) is an antibody targeting the CCR4 receptor, authorized for relapsed or refractory peripheral T-cell (PTCL) and cutaneous T-cell lymphomas (CTCL). Its adoption in guidelines and endorsement by FDA and EMA established it as a systemic treatment, especially for advanced disease stages due to its comparatively lower toxicity. Clinical trials and real-world evidence have underscored its efficacy in advanced CTCLs, including mycosis fungoides and Sézary syndrome; PTCLs; and adult T-cell leukemia/lymphoma (ATLL), showcasing positive outcomes. Notably, the drug has demonstrated significant response rates, disease stability, and extended periods of progression-free survival, suggesting its applicability in cases with multiple treatment lines. Its safety profile is generally manageable, with adverse events (AEs) primarily related to the skin, infusion-related reactions, drug eruptions, autoimmune diseases, and skin disorders. The latter seem to appear as CCR4 can promote the skin-specific homing of lymphocytes, and MOG is directed against this receptor. While combination with immunostimulatory agents like interferon alpha and interleukin 12 has shown promising results, caution is urged when combining with PD1 inhibitors due to the heightened risk of immune-mediated AEs. The introduction of MOG as a systemic treatment implies a significant advancement in managing these diseases, supported by its favorable safety profile and complementary mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Department, Hospital Universitario Ramón y Cajal, Instituto de Investigación Sanitaria Ramón y Cajal (Irycis), 28034 Madrid, Spain.
- Dermatology Department, Hospital 12 de Octubre, 28041 Madrid, Spain.
- Dermatology Department, Hospital del Mar, 08003 Barcelona, Spain.
- Dermatology Department, Hospital Universitario de la Princesa, Fundación de Investigación Biomédica de la Princesa, 28006 Madrid, Spain.
ORCID-Profile: Mar Llamas-Velasco
Förderung
- Kyowa Kirin
Zitieren
APA
Fernández-Guarino, M., Ortiz, P., Gallardo, F., & Llamas-Velasco, M. (2024). Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25042203
Vancouver
Fernández-Guarino M, Ortiz P, Gallardo F, Llamas-Velasco M. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25042203
BibTeX
@article{FernndezGuarino2024,
author = {Fernández-Guarino, Montserrat and Ortiz, Pablo and Gallardo, Fernando and Llamas-Velasco, Mar},
title = {Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25042203}
}
EUVIMED